USA flag logo/image

An Official Website of the United States Government

SBIR Phase II: Development of Novel Dendrimer-based Technologies for…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
Program Year/Program:
2013 / SBIR
Agency Tracking Number:
1256600
Solicitation Year:
2012
Solicitation Topic Code:
BC
Solicitation Number:
Small Business Information
Tymora
1281 Win Hentschel Blvd. West Lafayette, IN 47906-4182
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2013
Title: SBIR Phase II: Development of Novel Dendrimer-based Technologies for Phosphorylation Analyses
Agency: NSF
Contract: 1256600
Award Amount: $500,000.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase II project addresses the unmet needs for effective analysis of protein phosphorylation, a process where a phosphate group is added to a protein to change its function. Protein phosphorylation is a crucial modification of proteins; its abnormalities have been implicated in many diseases. Therefore, assessing the phosphorylation status of individual proteins or classes of proteins, qualitatively or quantitatively, has become a routine but extremely important step in the majority of life science research labs. Existing technologies have glaring deficiencies, including low reproducibility, poor recovery, high cost, reduced selectivity and prolonged experiment time. The platform technology to be developed during this Phase II project will greatly alleviate these shortcomings by providing lucrative, general approaches for phosphorylation analyses. The technologies will enable general phosphorylation detection, cost-effective cancer inhibitor screenings, and kinase/phosphatase activity quantitation for new drug discovery. The broader impact/commercial potential of this project is the development of platform technology to improve a set of biochemical assays, thus enabling the discovery of new therapeutic targets and drugs. Protein phosphorylation and kinase inhibitors as drug targets are currently at the peak of research and development (R & D), responsible for over 30% of the total drug discovery expenses. These R & D activities could greatly benefit from the proposed technologies due to their innovative design and versatile features for optimum efficiency, and the ability to reproducibly explore phosphorylation events in unprecedented depth. These should provide invaluable tools and address needs of many bioscience research labs/facilities in academic and industrial settings.

Principal Investigator:

Anton Iliuk
7654906834
anton.iliuk@tymora-analytical.com

Business Contact:

Anton Iliuk
7654906834
anton.iliuk@tymora-analytical.com
Small Business Information at Submission:

Tymora Analytical Operations, LLC
1281 Win Hentschel Blvd. West Lafayette, IN 47906-4182

EIN/Tax ID: 273867327
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No